Cargando…

Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options

Alveolar rhabdomyosarcoma (ARMS) represents a block in differentiation of malignant myoblasts. Genomic events implicated in the pathogenesis of ARMS involve PAX3-FKHR (FOXO1) or PAX7-FKHR (FOXO1) translocation with corresponding fusion transcripts and fusion proteins. Commonalities in ARMS include u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Robert E., Buryanek, Jamie, Katz, Amanda M., Paz, Keren, Wolff, Johannes E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216796/ https://www.ncbi.nlm.nih.gov/pubmed/27323832 http://dx.doi.org/10.18632/oncotarget.10089

Ejemplares similares

Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR–dependent motility in alveolar rhabdomyosarcoma cells
por: Liu, Lingling, et al.
Publicado: (2012)

Too much AKT turns PAX3-FKHR dead: A prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma
por: Jothi, Mathivanan, et al.
Publicado: (2012)

Structural and Functional Studies of FKHR-PAX3, a Reciprocal Fusion Gene of the t(2;13) Chromosomal Translocation in Alveolar Rhabdomyosarcoma
por: Hu, Qiande, et al.
Publicado: (2013)

Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
por: Anderson, J, et al.
Publicado: (2001)

Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma
por: AHN, EUN HYUN, et al.
Publicado: (2013)

Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options
por: Brown, Robert E., et al.
Publicado: (2017)

Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options
por: Loupe, J M, et al.
Publicado: (2015)

Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis
por: Marshall, Amy D, et al.
Publicado: (2012)

Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein
por: Nabarro, Stephen, et al.
Publicado: (2005)

PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
por: Akaike, Keisuke, et al.
Publicado: (2018)

Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells
por: Liu, Lingling, et al.
Publicado: (2013)

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
por: Milewski, David, et al.
Publicado: (2021)

PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
por: Searcy, Madeline B., et al.
Publicado: (2023)

Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis
por: Brown, Robert E., et al.
Publicado: (2017)

Modeling of the Human Alveolar Rhabdomyosarcoma Pax3-Foxo1 Chromosome Translocation in Mouse Myoblasts Using CRISPR-Cas9 Nuclease
por: Lagutina, Irina V., et al.
Publicado: (2015)

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma
por: Hanna, Jason A., et al.
Publicado: (2018)

Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options
por: Brown, Robert E., et al.
Publicado: (2016)

Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma
por: Regina, Carla, et al.
Publicado: (2021)

The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway
por: Schmitt-Ney, Michel, et al.
Publicado: (2015)

Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma
por: Nguyen, Thanh Hung, et al.
Publicado: (2018)

MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
por: Cassandri, Matteo, et al.
Publicado: (2021)

Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma
por: Kanayama, Takuyo, et al.
Publicado: (2021)

The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition
por: Gonzalez Curto, Gloria, et al.
Publicado: (2020)

FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma
por: Bois, Philippe R.J., et al.
Publicado: (2007)

FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma
por: Bois, Philippe R.J., et al.
Publicado: (2005)

Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor—Significance of Tumor Subclones
por: Skrzypek, Klaudia, et al.
Publicado: (2021)

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis
por: Kendall, Genevieve C, et al.
Publicado: (2018)

Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements
por: Vicente-García, Cristina, et al.
Publicado: (2017)

Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1)
por: Subbiah, Vivek, et al.
Publicado: (2013)

OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas
por: Kaleta, Magdalena, et al.
Publicado: (2019)

Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells
por: Yoshida, Hideki, et al.
Publicado: (2020)

ACTA1 is inhibited by PAX3-FOXO1 through RhoA-MKL1-SRF signaling pathway and impairs cell proliferation, migration and tumor growth in Alveolar Rhabdomyosarcoma
por: Hu, Qiande, et al.
Publicado: (2021)

Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs
por: Manceau, Line, et al.
Publicado: (2022)

Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining
por: Zhan, Xiaohui, et al.
Publicado: (2023)

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells
por: Walters, Zoë S, et al.
Publicado: (2013)

Refractory Hydroa Vacciniforme-like Lymphoma: Biological Insights from Morphoproteomic Analysis
por: Goswamy, Rohit, et al.
Publicado: (2022)

Alveolar rhabdomyosarcoma of maxilla
por: Ananthaneni, Anuradha, et al.
Publicado: (2016)

Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1
por: Sugito, Nobuhiko, et al.
Publicado: (2020)

Two further cases of t(2;13) in alveolar rhabdomyosarcoma indicating a review of the published chromosome breakpoints.
por: Rowe, D., et al.
Publicado: (1987)

Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma
por: Dehner, Carina A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vkbhtv2vthirneap04oeg885ib